The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics for AxSpA, which is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs), and their positioning as the first-line targeted agents is encouraged through payer policies. To overcome this challenge, the marketers of Cosentyx, Taltz, and emerging therapies, including UCB’s bimekizumab and Pfizer’s Xeljanz, need to understand how best to navigate the access and reimbursement environment, particularly because payers expect to increase their stringency for this indication in the coming years.

QUESTIONS ANSWERED

  • What are the patient-share leaders among AxSpA biologics, and which AxSpA agents do physicians and payers believe perform best on specific clinical and market access factors?
  • Are there differences in how payers view the different AxSpA subpopulations? What are the biggest reimbursement obstacles that AxSpA drugs face?
  • What are physicians’ perceptions of the emerging agents bimekizumab and Xeljanz, and how do payers anticipate covering these agents?
  • What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Table of contents

  • Axial Spondyloarthritis - Access & Reimbursement - Detailed, Expanded Analysis: Axial Spondyloarthritis (ankylosing Spondylitis And Nonradiographic Axial Spondyloarthritis) - US
    • Access and Reimbursement Axial Spondyloarthritis US August 2020

Author(s): Swati Kinger, M.B.A

Swati Kinger, M.B.A., is an associate analyst on the immune and inflammatory disorders team at Decision Resources Group. Prior to joining DRG, she was an associate consultant for a life sciences consulting firm, where she worked on syndicated offerings and ad-hoc requests involving patient journeys, market assessment and competitive intelligence. She holds a bachelor’s degree in pharmacy and an M.B.A. in Pharma from the National Institute of Pharmaceutical Education and Research, India.


Related Reports

Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) marke...

View Details

Axial Spondyloarthritis - Unmet Need - Detailed, Expanded Analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimz...

View Details

Ankylosing Spondylitis | Treatment Algorithms | Claims Data Analysis | US | 2020

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals...

View Details

Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

MARKET OUTLOOKAnkylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axi...

View Details